

October 11, 2023

Members of the Ohio Public Health Policy Committee Ohio Statehouse

RE: HB 177 - Protections Needed to Guard Against High Patient Cost-Sharing for Prescription Drugs

Dear Chairman Lipps, Vice-Chair Stewart, Ranking Member Liston and members of the Committee:

We, the undersigned 56 patient, provider, and consumer organizations, appreciate the House Public Health Policy Committee's work to consider House Bill 177. We ask for the committee's support of the legislation and urge for a vote by the entire Ohio House of Representatives.

Healthcare regulations and policies are a complicated combination of federal and state laws. So, while there is now a federal ruling related to copay accumulators which is a tremendous step forward, Rep. Susan Manchester, the bill sponsor, believes that H.B. 177 is still needed to protect Ohio patients.

If you recall, every current House member who also served during the 134th General Assembly voted for this language. The language that passed the House is now HB 177 and reflects what was negotiated last session between the bill sponsors and House Majority Floor Leader Bill Seitz.

Through House Bill 177, the Ohio General Assembly can reform discriminatory accumulator adjustment programs being used by various health insurance plans and pharmacy benefit managers (PBMs). This legislation would protect Ohioans with complex and life-threatening health conditions who depend on copayment assistance programs to cover out-of-pocket costs for specialty medications.

Similar legislation has been passed by nineteen states, including our neighboring states of West Virginia and Kentucky.

Key details about HB 177 you should know:

- 1. A copay accumulator ban will not increase employer health insurance premiums. Nineteen states and Puerto Rico have passed copay accumulator bans. Multiple studies have shown that a ban does not increase premiums. No evidence from those opposing this legislation has been provided to prove that it increases premiums. Please see the referenced studies below disproving opponents argument.
- 2. Insurers and PBM's divert manufacturer patient assistance intended for patients to the tune of more than 25% profit from the funds. The pirating of these funds causes patients higher out-of-pocket costs, which in turn causes patients to forgo care, increasing the burden on our healthcare system. This diversion of funds is so lucrative for the plans that they often offer their clients \$0 copays for medications. The 25% the plans confiscate is compounded because it is based on the drug's list price, far more than their actual cost for the medication.
- 3. <u>HB 177 is not a mandate</u>. This bill does not require health plans and PBMs to cover any additional benefit. It simply prohibits the discriminatory practices of health plans and PBMs refusing to apply all forms of cost-sharing assistance made on behalf of an enrollee to meet their rapidly escalating out-of-pocket obligations.

- 4. HB 177 does not interfere with health insurance plans cost saving utilization management tools and does not steer patients to more expensive drugs. The language specifically protects the insurer by allowing accumulator programs for certain cost-sharing requirements for a drug for which there is a medically generic equivalent. This bill preserves the rights of health plans and PBMs to use generic medications as they do now.
- 5. HB 177 was supported without opposition by the Prescription Drug Transparency and Affordability Council. This Council was created by the Ohio House during the 133rd General Assembly as part of the biennial budget bill (HB 166). This Council included state agency directors, patient advocacy group representatives, statewide business organization leaders, labor union leaders, mayors and others.

The need for House Bill 177 has only been exacerbated with the creation of copay maximizers, alternative funding programs and other roadblocks to prescription assistance.

We look forward to working with the members of the Ohio House of Representatives to pass HB 177 as quickly as possible. Together, as one voice, we urge you to ensure Ohio patients can afford their medications.

Sincerely,

Aimed Alliance

Academy of Medicine of Cleveland & Northern Ohio

AiArthritis

Allergy & Asthma Network Alliance for Patient Access

ALS Association

ALS United Central & Southern Ohio

American Cancer Society Cancer Action Network

American College of Rheumatology American Diabetes Association

American Kidney Fund

Association for Clinical Oncology

BDRSA Foundation Biomarker Collaborative Chronic Care Policy Alliance Chronic Disease Coalition

Coalition of State Rheumatology Organizations Down Syndrome Association of Central Ohio

Equitas Health Exon 20 Group

Oncology Alliance

Gaucher Community Alliance Global Healthy Living Foundation Hemophilia Federation of America HIV+Hepatitis Policy Institute

ICAN, International Cancer Advocacy Network

Immune Deficiency Foundation Infusion Access Foundation Rare Access Action Project National Alliance on Mental Illness of Ohio Lupus and Allied Disease Association, Inc. Movement Disorders Policy Coalition National Bleeding Disorders Foundation Mental Health America of Ohio

MET Crusaders

Movement Disorders Policy Coalition
National Bleeding Disorders Foundation

National Eczema Association

National Infusion Center Association National Psoriasis Foundation Ohio Association of Rheumatology Ohio Bleeding Disorders Council

Ohio Chapter of the American College of Cardiology

Ohio Dermatological Association

Ohio Foot and Ankle Medical Association Community

Ohio Gastroenterology Society
Ohio Hematology Oncology Society

Ohio Life Sciences

Ohio Osteopathic Association Ohio Pharmacists Association

Ohio Psychiatric Physicians Association

Ohio Psychological Association

Ohio Sickle Cell and Health Association

Ohio State Medical Association

PD-L1 Amplifieds

Spondylitis Association of America

The AIDS Institute

US Hereditary Angioedema Association

C: Majority Floor Leader Bill Seitz Minority Leader Allison Russo Rep. Jay Edwards Rep. Jeff LaRe Rep. Susan Manchester

Attachments:

- 1. **Global Healthy Living Foundation Press Release:** States With Laws Protecting Patient Assistance Programs Have Not Seen Health Insurance Premium Hikes; https://ghlf.org/copay-assistance-protection/
- 2. **The AIDS Institute:** Comparison of Marketplace Average Benchmark Premiums Between States With and Without Copay; https://aidsinstitute.net/documents/Copay-Assistance-Does-Not-Increase-Premiums-Final.pdf